Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04064671

ZEPHYR: A Study Evaluating Surgical Outcome After Implantation of the Zephyr ZSI 475 FTM Inflatable Penile Implant in the Neophallus After Female-to-male Sex Reassignment Surgery

This study will look into the surgical outcome after implantation of the Zephyr ZSI 475 FTM in the neophallus.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Urology, Ghent University Hospital

Ghent, Oost-Vlaanderen, 9000, Belgium

Location status: Recruiting

Location contact

Piet Hoebeke, MD, PhD

PRINCIPAL_INVESTIGATOR

Wesley Verla

CONTACT

[email protected]

+32 9 332 22 76

Wesley Verla, MD

SUB_INVESTIGATOR

About this study

Obtaining erectile function after phalloplasty in female-to-male transsexuals remains a challenging issue and requires the implantation of a device. For biological males, several erectile implants exist and widespread research has demonstrated the successful outcome of these devices. However, substantial differences exist between a native penis and a neophallus and explain the poorer outcome of these devices in female-to-male transsexuals.

In 2018, Falcone et al. published the largest retrospective series on this subject so far and reported that after a mean follow-up of 20 months, only 58% of their patients still had their original implant in place. The main obstacle in these female-to-male transsexuals is represented by the lack of corpora cavernosa in the neophallus which leads to difficult anchorage of the prosthesis, little stability of the prosthesis and a higher risk of cylinder erosion.

Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.

So far, no literature regarding surgical or functional outcome of the Zephyr ZSI 475 FTM exists. The aim of this study is to prospectively collect data of all female-to-male transsexuals that are treated with the implantation of this device at Ghent University Hospital.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations.
  • Age ≥ 18 years.
  • Female-to-male transsexual patient.
  • Implantation of Zephyr ZSI 475 FTM erectile device.

Exclusion criteria

  • Absence of signed written informed consent.
  • Age < 18 years.
  • Biological males.
  • Patients opting for penile implants other than the Zephyr ZSI 475 FTM.

Treatment and study plan

Implantation of the Zephyr ZSI 475 FTM erectile implant

Other

Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.

Primary outcomes

  1. Explantation-free survival

    Time frame: From date of surgery until the date of explantation or date of death from any cause, whichever came first, assessed up to 120 months postoperatively (assessment at 3 months postoperatively, 1 year postoperatively and then yearly)

    Interval between implantation date and explantation date (if explanted)

Secondary outcomes

  1. Complication rate after implantation of this device

    Time frame: 90 days after implantation

    The Clavien-Dindo system (<90d) to report surgical complications will be used

  2. Type of complications

    Time frame: From date of surgery until the date of explantation or date of death from any cause, whichever came first, assessed up to 120 months postoperatively (assessment at 3 months postoperatively, 1 year postoperatively and then yearly)

    Complications that will be assessed, involve:

    • Urinary tract infection (yes or no)
    • Hematuria (yes or no)
    • Wound infection (yes or no)
    • Wound dehiscence (yes or no)
    • Abscess formation (yes or no)
    • Fistula formation (yes or no)
    • Protrusion of the device (yes or no)
    • Malfunction of the device (yes or no)
    • migration of the device (yes or no)
    • Infection of the device (yes or no)

Study contacts

Contact information is provided by the study sponsor or research team.

Wesley Verla

CONTACT

[email protected]

+32 9 332 22 76

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Registry information

Official study title

ZEPHYR: A Prospective Study Evaluating Surgical Outcome After Implantation of the Zephyr ZSI 475 FTM Inflatable Penile Implant in the Neophallus After Female-to-male Sex Reassignment Surgery

Important dates

Study start
2017
Primary completion
2027
Study completion
2029
First posted
Aug 22, 2019
Registry last updated
Jan 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.